People with chronic hives should be tested for thyroid autoimmunity to manage their condition better.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
2 citations
,
September 2025 in “Scientific Reports” Women with PCOS are more likely to have thyroid antibodies than those without.
April 2018 in “Journal of Investigative Dermatology” The role of γδT-cells in causing alopecia areata remains unclear.
November 2022 in “Chinese Journal of Dermatology” Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.
6 citations
,
May 2013 in “The Journal of Dermatology” Autoimmune reactions may cause both alopecia areata and HAM.
8 citations
,
April 2023 in “Dermatology Practical & Conceptual” Certain blood markers, especially MLR, can help diagnose alopecia areata.
71 citations
,
February 1992 in “Journal of Cutaneous Pathology” Antibodies help identify glycoproteins in normal skin and tumor cells.
2 citations
,
January 2021 in “Case reports in endocrinology” The girl's condition improved with treatment, showing no new autoimmune diseases and hair regrowth.
CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.
June 2024 in “British Journal of Dermatology” Dermatologists vary widely in testing practices for alopecia areata, often exceeding guideline recommendations.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.
33 citations
,
October 2006 in “European Journal of Immunology” The CD44-CD49d complex boosts T cell activation and survival in autoimmune disease.
7 citations
,
July 2024 in “Dermatology Practical & Conceptual” SII is a useful and affordable tool to assess and monitor alopecia areata.
3 citations
,
July 2025 in “Clinical and Experimental Dermatology” Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
1 citations
,
January 2009 in “Kidney International” The woman was diagnosed with systemic lupus erythematosus (SLE) after initial misdiagnosis and improved with proper treatment.
March 2025 in “Clinical and Experimental Dermatology” Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
2 citations
,
October 2022 in “Current Allergy and Asthma Reports” Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.
71 citations
,
May 2019 in “Rheumatology” Tph cells are linked to the severity of systemic lupus erythematosus.
March 2019 in “Journal of medical science and clinical research” Skin problems are common and early signs of Systemic Lupus Erythematosus, and certain immune system markers are important for diagnosis and treatment.
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
3 citations
,
November 2005 in “Journal of Investigative Dermatology Symposium Proceedings” Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.
12 citations
,
March 2016 in “BBA clinical” Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.
14 citations
,
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.
September 2025 in “Diseases” Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.
August 2023 in “Research Square (Research Square)” Melanocytes may trigger the immune response in alopecia areata, affecting hair regrowth.
3 citations
,
July 2021 in “International journal of environmental research and public health/International journal of environmental research and public health” Two patients developed complete hair loss after Alemtuzumab treatment for MS, with no regrowth after two years.
7 citations
,
October 2024 in “Frontiers in Immunology” A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.
December 2025 in “Cureus” Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.